Phosphoinositide 3-kinase in Health and Disease: Volume 2

Description

From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here Front Matter....Pages i-x PI3K: From the Bench to the Clinic and Back....Pages 1-19 Oncogenic Mutations of PIK3CA in Human Cancers....Pages 21-41 Structural Effects of Oncogenic PI3Kα Mutations....Pages 43-53 Comparing the Roles of the p110α and p110β Isoforms of PI3K in Signaling and Cancer....Pages 55-77 Phosphatidylinositol 3-Kinase: The Oncoprotein....Pages 79-104 AKT Signaling in Physiology and Disease....Pages 105-133 Faithfull Modeling of PTEN Loss Driven Diseases in the Mouse....Pages 135-168 PI3K as a Target for Therapy in Haematological Malignancies....Pages 169-188 Clinical Development of Phosphatidylinositol-3 Kinase Pathway Inhibitors....Pages 189-208 From the Bench to the Bed Side: PI3K Pathway Inhibitors in Clinical Development....Pages 209-239 New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs)....Pages 241-262 Small Molecule Inhibitors of the PI3-Kinase Family....Pages 263-278 Targeting the RTK-PI3K-mTOR Axis in Malignant Glioma: Overcoming Resistance....Pages 279-296 Back Matter....Pages 297-304